Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 1/20 | 0.55 |
| ▸ | ADRA2C | P18825 | 4/20 | 0.49 |
| ▸ | ADRA2A | P08913 | 3/20 | 0.49 |
| ▸ | ADRA2B | P18089 | 3/20 | 0.49 |
| ▸ | HTR1A | P08908 | 3/20 | 0.49 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.49 |
| ▸ | ADRB2 | P07550 | 3/20 | 0.48 |
| ▸ | ADRB1 | P08588 | 3/20 | 0.48 |
| ▸ | LMNA | P02545 | 2/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.48 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.48 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.48 |
| ▸ | BDKRB2 | P30411 | 1/20 | 0.48 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.48 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.48 |
| ▸ | HTR2B | P41595 | 1/20 | 0.48 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1036878 | 0.87 | ADRA2C (0.48) | KMT2AADRA2CADRA2AADRA2BHTR1A | |
| SCHEMBL289668 | 0.85 | ADRA2C (0.49) | KMT2AADRA2CADRA2AADRA2BHTR1A | |
| SCHEMBL1876475 | 0.84 | NPSR1 (0.50) | KMT2AADRA2CHTR1AKCNH2ADRB2 | |
| SCHEMBL8935860 | 0.82 | KDM4E (0.45) | KMT2AADRA2CADRA2AADRA2BHTR1A | |
| SCHEMBL8935855 | 0.82 | KDM4E (0.45) | KMT2AADRA2CADRA2AADRA2BHTR1A | |
| SCHEMBL11052071 | 0.82 | KMT2A (0.64) | KMT2AADRA2CADRA2AADRA2BCYP1A2 | |
| SCHEMBL1039586 | 0.82 | ADRA2C (0.47) | KMT2AADRA2CADRA2AADRA2BHTR1A | |
| SCHEMBL1325928 | 0.81 | ADRB2 (0.56) | KMT2AADRA2CADRA2AADRA2BHTR1A | |
| SCHEMBL7934338 | 0.81 | KMT2A (0.62) | KMT2ACYP1A2HTR2BTSHRTDP1 | |
| SCHEMBL7087891 | 0.81 | KMT2A (0.62) | KMT2ACYP1A2HTR2BTSHRKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2427469-B1 | PROCESS FOR THE PREPARATION OF RUTHENIUM METATHESIS COMPLEX CATALYSTS | HOFFMANN LA ROCHE (CH) | 2013-12-11 | — | — | EP | disclosed |
| US-8288534-B2 | Process for the preparation a ruthenium complex | ROCHE PALO ALTO LLC (US) | 2012-10-16 | — | — | US | disclosed |
| EP-2276725-B1 | NEW RUTHENIUM COMPLEXES AS CATALYSTS FOR METATHESIS REACTIONS | HOFFMANN LA ROCHE (CH) | 2012-07-04 | — | — | EP | disclosed |
| EP-2427469-A1 | PROCESS FOR THE PREPARATION OF RUTHENIUM METATHESIS COMPLEX CATALYSTS | F. Hoffmann-La Roche AG (CH) | 2012-03-14 | — | — | EP | disclosed |
| US-7939668-B2 | Ruthenium complexes as catalysts for metathesis reactions | ROCHE PALO ALTO LLC (US) | 2011-05-10 | — | — | US | disclosed |
| EP-2276725-A1 | NEW RUTHENIUM COMPLEXES AS CATALYSTS FOR METATHESIS REACTIONS | F. Hoffmann-La Roche AG (CH) | 2011-01-26 | — | — | EP | disclosed |
| WO-2010127964-A1 | PROCESS FOR THE PREPARATION OF RUTHENIUM METATHESIS COMPLEX CATALYSTS | F. HOFFMANN-LA ROCHE AG (CH) | 2010-11-11 | — | — | WO | disclosed |
| US-20100286403-A1 | PROCESS FOR THE PREPARATION A RUTHENIUM COMPLEX | ROCHE PALO ALTO LLC | 2010-11-11 | — | — | US | disclosed |
| US-20090275714-A1 | New Ruthenium Complexes as Catalysts for Metathesis Reactions | ROCHE PALO ALTO LLC | 2009-11-05 | — | — | US | disclosed |
| WO-2009124853-A1 | NEW RUTHENIUM COMPLEXES AS CATALYSTS FOR METATHESIS REACTIONS | F. HOFFMANN-LA ROCHE AG (CH) | 2009-10-15 | — | — | WO | disclosed |
| US-4465494-A | FOR ENGINES OR BURNERS | SOCIETE NATIONALE ELF AQUITAINE (FR) | 1984-08-14 | — | — | US | disclosed |
| EP-0058605-A2 | Microemulsion of water in a liquid combustible | SOCIETE NATIONALE ELF AQUITAINE (FR) | 1982-08-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100286403-A1 | PROCESS FOR THE PREPARATION A RUTHENIUM COMPLEX | CYP3A4, CYP3A5, CYP3A7 | KMT2A 4269/4885ADRA2C 1561/4885ADRA2A 2432/4885 |
| US-20090275714-A1 | New Ruthenium Complexes as Catalysts for Metathesis Reactions | HABP2, CYP3A7, ACE | KMT2A 4270/4885ADRA2C 4712/4885ADRA2A 4822/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.